Thermo Fisher Scientific Inc (TMO): Today's Featured Health Care Winner

Thermo Fisher Scientific was a winner within the health care sector, rising 93 cents (1.6%) to $60.69 on average volume.
By TheStreet Wire ,

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

.

Thermo Fisher Scientific

(

TMO

) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.1%. By the end of trading, Thermo Fisher Scientific rose 93 cents (1.6%) to $60.69 on average volume. Throughout the day, 2.1 million shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.8 million shares. The stock ranged in a price between $59.61-$60.94 after having opened the day at $59.98 as compared to the previous trading day's close of $59.76. Other companies within the Health Care sector that increased today were:

NABI Biopharmaceuticals

(

NABI

), up 495.4%,

Kips Bay Medical

(

KIPS

), up 33%,

Cytori Therapeutics

(

CYTX

), up 18.9%, and

Sequenom

(

SQNM

), up 18.8%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $21.92 billion and is part of the health services industry. The company has a P/E ratio of 19.4, above the S&P 500 P/E ratio of 17.7. Shares are up 35.3% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front,

CombiMatrix Corporation

(

CBMX

), down 45.1%,

OxiGene

(

OXGN

), down 21.4%,

SciClone Pharmaceuticals

(

SCLN

), down 19.4%, and

Palatin Technologies

(

PTN

), down 15.2%, were all laggards within the health care sector with

Cigna

(

CI

) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!

.

null

Loading ...